2017.02.04 03:23
, MD, MHA
Email the author MD, MHA Sripal Bangalore,
, MD,
, MD,
, MD,
, MD,
, MD,
, MD
Published Online: January 18, 2017
DOI: http://dx.doi.org/10.1016/j.amjmed.2017.01.004
Publication stage: In Press Accepted Manuscript
The optimal blood pressure (BP) target has been a matter of debate. The recent SPRINT trial showed significant benefits of a BP target of <120 mm Hg albeit with an increase in serious adverse effects related to low BP.
PUBMED, EMBASE, and CENTRAL were searched for randomized trials comparing treating to different BP targets. Trial arms were grouped into five systolic BP target categories: 1) <160 mm Hg; 2) <150 mm Hg; 3) <140 mm Hg; 4) <130 mm Hg and 5) <120 mm Hg. Efficacy outcomes of stroke, myocardial infarction, death, cardiovascular death, heart failure and safety outcomes of serious adverse effects were evaluated using a network meta-analysis.
Seventeen trials that enrolled 55,163 patients with 204,103 patient-years of follow-up were included. There was a significant decrease in stroke (RR=0.54; 95% CI 0.29-1.00) and myocardial infarction (RR=0.68; 95% CI 0.47-1.00) with systolic BP <120 mm Hg (vs. <160 mm Hg). Sensitivity analysis using achieved systolic BP showed a 72%, 97% and 227% increase in stroke with systolic BP of <140 mm Hg, <150 mm Hg and <160 mm respectively, when compared with systolic BP <120 mm Hg. There was no difference in death, cardiovascular death or heart failure when comparing any of the BP targets. However, the point estimate favored lower BP targets (<120 mm Hg, <130 mm Hg) when compared with higher BP targets (<140 mm Hg or <150 mm Hg). BP targets of <120 mm Hg and <130 mm Hg ranked #1 and #2 respectively, as the most efficacious target. There was a significant increase in serious adverse effects with systolic BP <120 mm Hg vs. <150 mm Hg (RR=1.83; 95% CI 1.05-3.20) or vs. <140 mm Hg (RR=2.12; 95% CI 1.46-3.08). BP targets of <140 mm Hg and <150 mm Hg ranked #1 and #2 respectively, as the safest target for the outcome of serious adverse effects. Cluster plots for combined efficacy and safety showed that a systolic BP target of <130 mm Hg had optimal balance between efficacy and safety.
In patients with hypertension, a systolic BP target of <130 mm Hg achieved optimal balance between efficacy and safety.
blood pressure, myocardial infarction, systolic, stroke, target
Disclosures: None of the authors received any compensation for their work on this manuscript.
No. | Subject | Date | Author | Last Update | Views |
---|---|---|---|---|---|
Notice | How to write your comments onto a webpage [2] | 2016.07.06 | 운영자 | 2016.11.20 | 18194 |
Notice | How to Upload Pictures in webpages | 2016.07.06 | 운영자 | 2018.10.19 | 32352 |
Notice | How to use Rich Text Editor [3] | 2016.06.28 | 운영자 | 2018.10.19 | 5929 |
Notice | How to Write a Webpage | 2016.06.28 | 운영자 | 2020.12.23 | 43842 |
663 | ♥ 뇌졸중 -1 [1] | 2009.08.11 | 이종구*57 | 2009.08.11 | 8392 |
662 | ♥ 뇌졸증-2 [1] | 2009.08.17 | 이종구*57 | 2009.08.17 | 9474 |
661 | ♥ 뇌졸증-3 | 2009.08.24 | 이종구*57 | 2009.08.24 | 8174 |
660 | ♥ 아스피린과 심혈관질환 및 대장암 [1] | 2009.08.31 | 이종구*57 | 2009.08.31 | 8933 |
659 | ♥ 고혈압-1 [2] | 2009.09.07 | 이종구*57 | 2009.09.07 | 9396 |
658 | ♥ 고혈압-2 | 2009.09.14 | 이종구*57 | 2009.09.14 | 9445 |
657 | ♥ 고혈압-3 [1] | 2009.09.21 | 이종구*57 | 2009.09.21 | 9883 |
656 | ♥ 고혈압-4 | 2009.09.28 | 이종구*57 | 2009.09.28 | 9419 |
655 | ♥ 당뇨병과 심장병 [1] | 2009.10.05 | 이종구*57 | 2009.10.05 | 6511 |
654 | Chronic Fatigue Syndrome - Viral origin ? [5] | 2009.10.09 | 운영자 | 2009.10.09 | 5837 |
653 | ♥ 악성, 양성 콜레스테롤, 중성지방, 대사증후군-1 | 2009.10.12 | 이종구*57 | 2009.10.12 | 10663 |
652 | ♥ 악성, 양성 콜레스테롤, 중성지방, 대사증후군-2 [1] | 2009.10.19 | 이종구*57 | 2009.10.19 | 10118 |
651 | ♥ 악성, 양성콜레스테롤, 중성지방, 대사증후군-3 [1] | 2009.10.26 | 이종구*57 | 2009.10.26 | 9890 |
650 | ♥ 비만과 건강-1 | 2009.11.02 | 이종구*57 | 2009.11.02 | 9663 |
649 | ♥ 비만과 건강-2 [1] | 2009.11.09 | 이종구*57 | 2009.11.09 | 8521 |
648 | ♥ 비만과 건강-3 [1] | 2009.11.16 | 이종구*57 | 2009.11.16 | 7335 |
647 | 술! 적당히 마시면 심혈관 질환 예방 [5] | 2009.11.18 | 이종구*57 | 2009.11.18 | 6503 |
646 | 영국 고혈압학회가 제시하는 고혈압치료의 새로운 지침 | 2009.11.23 | 이종구*57 | 2009.11.23 | 7939 |
645 | ♥ 고혈압 치료와 뇌졸중의 예방, 고혈압 치료제의 차이점은 무엇인가? | 2009.11.30 | 이종구*57 | 2009.11.30 | 7086 |
644 | ♥ 심장병을 예방하는 10가지 비결 | 2009.12.02 | 이종구*57 | 2009.12.02 | 7128 |
Under the ideal conditions the best way to avoid the side effects, i.e. unexpected drop or rise in systolic BP,
is close monitoring of BP and the fine tuning of the medicine dosages through
the close communication with the treating physician.
Not only the patient but also the doctor often doesn't realize how much fluctuation in BP there is
so that the patient winds up being under or over treated.
It cannot be overemphasized how important the close monitoring of BP is
as this article illustrates.